The patent relates to pharmaceutical Anti-TNF-Alfa antibody formulation.
Brief outline of the case
Following two oppositions and one intervention, the patent was revoked. The proprietor appealed.
During the OP before the board, Opponents 1-3 withdrew their oppositions.